clinical trial · NCT06488924
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
JCR Pharmaceuticals Co., Ltd.·phase2·recruiting·n = 10
Mucopolysaccharidosis III-BJR-446
brief summary
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
started
Nov 5, 2024
primary completion
Apr 30, 2030
completion
Apr 30, 2030
last updated
Sep 2, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol